Rui Yu1,2, Deming Tan3, Qin Ning4, Junqi Niu5, Xuefan Bai6, Shijun Chen7, Jun Cheng8, Yanyan Yu9, Hao Wang10, Min Xu11, Guangfeng Shi12, Mobin Wan13, Xinyue Chen14, Hong Tang15, Jifang Sheng16, Xiaoguang Dou17, Junping Shi18, Hong Ren19, Maorong Wang20, Hongfei Zhang21, Zhiliang Gao22, Chengwei Chen23, Hong Ma24, Jidong Jia24, Jinlin Hou1, Qing Xie25, Jian Sun1. 1. Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China. 2. Department of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 3. Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China. 4. Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 5. Hepatology Unit, No. 1 Hospital affiliated to Jilin University, Changchun, China. 6. Department of Infectious Diseases, Tangdu Hospital, Xi'an, China. 7. Ji'nan Infectious Diseases Hospital, Ji'nan, China. 8. Beijing Ditan Hospital, Beijing, China. 9. Department of Infectious Diseases, First Hospital of Peking University, Beijing, China. 10. Hepatology Unit, Peking University People's Hospital, Beijing, China. 11. 8th People's Hospital, Guangzhou, China. 12. Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. 13. Department of Infectious Diseases, Changhai Hospital, Shanghai, China. 14. Beijing Youan Hospital, Beijing, China. 15. Department of Infectious Diseases, West China Hospital, Chengdu, China. 16. Department of Infectious Diseases, Zhejiang University 1st Affiliated Hospital, Hangzhou, China. 17. Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China. 18. 6th People's Hospital, Hangzhou, China. 19. Department of Infectious Diseases, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. 20. Department of Infectious Diseases, 81st PLA Hospital, Nanjing, China. 21. 302nd PLA Hospital, Beijing, China. 22. Department of Infectious Diseases, Sun Yat-Sen University 3rd Affiliated Hospital, Guangzhou, China. 23. Department of Infectious Diseases, 85th PLA Hospital, Shanghai, China. 24. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. 25. Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Abstract
AIM: The role of vitamin D in individuals with chronic hepatitis B (CHB) is unclear. We aimed to explore the association of baseline vitamin D level with genetic determinants and week-104 treatment outcome in CHB patients. METHODS:Baseline serum 25-hydroxycholecalciferol (25(OH)D) levels and genetic polymorphism within GC, DHCR7, and CYP2R1 were determined in stored serum of 560 patients who were enrolled into a multicenter, randomized, controlled study and completed 104 weeks of telbivudine monotherapy or telbivudine-based optimized therapy. Virologic response was defined as hepatitis B virus DNA <300 copies/mL (52 IU/mL) at week 104. RESULTS: The mean 25(OH)D value was 29.64 ng/mL. The percentage of patients with vitamin D insufficiency (<30 ng/mL) and vitamin D deficiency (<20 ng/mL) were 55.0% and 20.9%, respectively. Gender, season, latitude, and GC rs2282679 polymorphism were independent factors of vitamin D status. Patients with sufficient vitamin D (≥30 ng/mL) achieved a higher virologic response rate than those with vitamin D insufficiency (81.7% vs. 67.2%, P < 0.001). The area under the curve of 25(OH)D to predict virologic response was 0.65 (P < 0.001; 95% confidence interval, 0.62-0.67). On multivariate analysis, 25(OH)D level was an independent predictor of virologic response, but not associated with hepatitis B envelope antigen (HBeAg) seroconversion or alanine aminotransferase (ALT) normalization. CONCLUSIONS:Vitamin D insufficiency was highly prevalent in treatment-naïve CHB patients in mainland China. Latitude and genetic determinants affect vitamin D status. Baseline vitamin D level can predict week-104 virologic response, but not HBeAg seroconversion or ALT normalization.
RCT Entities:
AIM: The role of vitamin D in individuals with chronic hepatitis B (CHB) is unclear. We aimed to explore the association of baseline vitamin D level with genetic determinants and week-104 treatment outcome in CHB patients. METHODS: Baseline serum 25-hydroxycholecalciferol (25(OH)D) levels and genetic polymorphism within GC, DHCR7, and CYP2R1 were determined in stored serum of 560 patients who were enrolled into a multicenter, randomized, controlled study and completed 104 weeks of telbivudine monotherapy or telbivudine-based optimized therapy. Virologic response was defined as hepatitis B virus DNA <300 copies/mL (52 IU/mL) at week 104. RESULTS: The mean 25(OH)D value was 29.64 ng/mL. The percentage of patients with vitamin Dinsufficiency (<30 ng/mL) and vitamin D deficiency (<20 ng/mL) were 55.0% and 20.9%, respectively. Gender, season, latitude, and GC rs2282679 polymorphism were independent factors of vitamin D status. Patients with sufficient vitamin D (≥30 ng/mL) achieved a higher virologic response rate than those with vitamin Dinsufficiency (81.7% vs. 67.2%, P < 0.001). The area under the curve of 25(OH)D to predict virologic response was 0.65 (P < 0.001; 95% confidence interval, 0.62-0.67). On multivariate analysis, 25(OH)D level was an independent predictor of virologic response, but not associated with hepatitis B envelope antigen (HBeAg) seroconversion or alanine aminotransferase (ALT) normalization. CONCLUSIONS:Vitamin Dinsufficiency was highly prevalent in treatment-naïve CHB patients in mainland China. Latitude and genetic determinants affect vitamin D status. Baseline vitamin D level can predict week-104 virologic response, but not HBeAg seroconversion or ALT normalization.
Authors: Nghiem Xuan Hoan; Hoang Van Tong; Le Huu Song; Christian G Meyer; Thirumalaisamy P Velavan Journal: World J Gastroenterol Date: 2018-01-28 Impact factor: 5.742
Authors: Nghiem Xuan Hoan; Nguyen Khuyen; Dao Phuong Giang; Mai Thanh Binh; Nguyen Linh Toan; Do Tuan Anh; Ngo Tat Trung; Mai Hong Bang; Christian G Meyer; Thirumalaisamy P Velavan; Le Huu Song Journal: BMC Med Genet Date: 2019-12-21 Impact factor: 2.103